SG11202100170RA - Antibody molecules that bind pd-l1 and cd137 - Google Patents
Antibody molecules that bind pd-l1 and cd137Info
- Publication number
- SG11202100170RA SG11202100170RA SG11202100170RA SG11202100170RA SG11202100170RA SG 11202100170R A SG11202100170R A SG 11202100170RA SG 11202100170R A SG11202100170R A SG 11202100170RA SG 11202100170R A SG11202100170R A SG 11202100170RA SG 11202100170R A SG11202100170R A SG 11202100170RA
- Authority
- SG
- Singapore
- Prior art keywords
- bind
- antibody molecules
- antibody
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811405.8A GB201811405D0 (en) | 2018-07-12 | 2018-07-12 | Antibody molecules that bind PD-L1 and CD137 |
| GBGB1818283.2A GB201818283D0 (en) | 2018-11-09 | 2018-11-09 | Antibody molecules that bind PD-L1 and CD137 |
| GBGB1902594.9A GB201902594D0 (en) | 2019-02-26 | 2019-02-26 | Antibody molecules that bind pd-l1 and cd137 |
| PCT/EP2019/068793 WO2020011964A1 (en) | 2018-07-12 | 2019-07-12 | Antibody molecules that bind pd-l1 and cd137 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100170RA true SG11202100170RA (en) | 2021-02-25 |
Family
ID=67303457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100170RA SG11202100170RA (en) | 2018-07-12 | 2019-07-12 | Antibody molecules that bind pd-l1 and cd137 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220049007A1 (en) |
| EP (1) | EP3820569A1 (en) |
| JP (2) | JP7360440B2 (en) |
| KR (1) | KR20210030956A (en) |
| CN (1) | CN112423845B (en) |
| AU (1) | AU2019301204A1 (en) |
| BR (1) | BR112021000394A2 (en) |
| CA (1) | CA3106046A1 (en) |
| IL (1) | IL280004A (en) |
| MX (1) | MX2021000398A (en) |
| SG (1) | SG11202100170RA (en) |
| TW (1) | TW202005984A (en) |
| WO (1) | WO2020011964A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| JP7489316B2 (en) | 2017-12-19 | 2024-05-23 | エフ－スター セラピューティクス リミテッド | FC-binding fragment having PD-LI antigen-binding site |
| JP7332627B2 (en) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | Optimized anti-TL1A antibody |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| JP7504992B2 (en) | 2019-10-24 | 2024-06-24 | プロメテウス バイオサイエンシーズ，インク． | Humanized antibodies against TNF-like ligand 1A (TL1A) and uses thereof |
| WO2021156326A1 (en) * | 2020-02-04 | 2021-08-12 | Genmab A/S | Antibodies for use in therapy |
| JP7434593B2 (en) * | 2020-05-14 | 2024-02-20 | エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド | Anti-PD-L1 antibody and anti-PD-L1/IL10 fusion protein |
| AU2022339953A1 (en) * | 2021-09-03 | 2024-02-29 | Novarock Biotherapeutics, Ltd. | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF |
| CN114702569B (en) * | 2022-05-25 | 2023-01-10 | 深圳吉诺因生物科技有限公司 | PD-L1 related vaccine and application thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1994016730A1 (en) | 1993-01-28 | 1994-08-04 | Sandoz Pharmaceutical Corporation | Human monoclonal antibodies to cytomegalovirus |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| ES2323651T3 (en) | 2005-01-05 | 2009-07-22 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | IMMUNOGLOBULIN SYNTHETIC DOMAINS WITH UNION PROPERTIES DEVELOPED BY ENGINEERING IN MOLECULA REGIONS DIFFERENT FROM THE REGIONS THAT DETERMINE COMPLEMENTARITY. |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| KR20190069615A (en) | 2008-12-09 | 2019-06-19 | 제넨테크, 인크. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| RU2710717C2 (en) | 2010-09-09 | 2020-01-10 | Пфайзер Инк. | Molecules which bind to 4-1bb |
| EP3292148B1 (en) | 2015-05-04 | 2024-01-24 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| CN108976300B (en) * | 2015-07-30 | 2023-04-14 | 宏观基因有限公司 | PD-1 binding molecules and methods of use thereof |
| SG10201912405TA (en) | 2016-01-11 | 2020-02-27 | Inhibrx Inc | Multivalent and multispecific 41bb-binding fusion proteins |
| CA3038020A1 (en) | 2016-09-23 | 2018-03-29 | Merus N.V. | Bispecific binding molecules that bind cd137 |
| WO2019025545A1 (en) | 2017-08-04 | 2019-02-07 | Genmab A/S | Binding agents binding to pd-l1 and cd137 and use thereof |
-
2019
- 2019-07-12 KR KR1020217003611A patent/KR20210030956A/en unknown
- 2019-07-12 TW TW108124754A patent/TW202005984A/en unknown
- 2019-07-12 CN CN201980046597.4A patent/CN112423845B/en active Active
- 2019-07-12 CA CA3106046A patent/CA3106046A1/en active Pending
- 2019-07-12 SG SG11202100170RA patent/SG11202100170RA/en unknown
- 2019-07-12 MX MX2021000398A patent/MX2021000398A/en unknown
- 2019-07-12 BR BR112021000394-0A patent/BR112021000394A2/en unknown
- 2019-07-12 AU AU2019301204A patent/AU2019301204A1/en active Pending
- 2019-07-12 EP EP19740347.0A patent/EP3820569A1/en active Pending
- 2019-07-12 WO PCT/EP2019/068793 patent/WO2020011964A1/en active Application Filing
- 2019-07-12 JP JP2021500385A patent/JP7360440B2/en active Active
- 2019-07-12 US US17/259,791 patent/US20220049007A1/en active Pending
-
2021
- 2021-01-07 IL IL280004A patent/IL280004A/en unknown
-
2023
- 2023-09-29 JP JP2023169756A patent/JP2023181176A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3106046A1 (en) | 2020-01-16 |
| JP2023181176A (en) | 2023-12-21 |
| IL280004A (en) | 2021-03-01 |
| MX2021000398A (en) | 2021-05-27 |
| AU2019301204A1 (en) | 2021-02-25 |
| US20220049007A1 (en) | 2022-02-17 |
| EP3820569A1 (en) | 2021-05-19 |
| WO2020011964A1 (en) | 2020-01-16 |
| TW202005984A (en) | 2020-02-01 |
| CN112423845A (en) | 2021-02-26 |
| JP7360440B2 (en) | 2023-10-12 |
| BR112021000394A2 (en) | 2021-04-06 |
| CN112423845B (en) | 2024-07-30 |
| KR20210030956A (en) | 2021-03-18 |
| JP2021524268A (en) | 2021-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280004A (en) | Antibody molecules that bind pd-l1 and cd137 | |
| HK1247213A1 (en) | Pd-l1 antibody, antigen fragment binding thereof and pharmaceutical use thereof | |
| IL260846B (en) | Antigen binding proteins that bind pd-l1 | |
| IL287565B1 (en) | Antibodies that bind cd39 and uses thereof | |
| IL280002A (en) | Antibody molecules that bind cd137 and ox40 | |
| DK3370768T3 (en) | ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND USES THEREOF | |
| ZA202003641B (en) | Antibodies binding ctla-4 and uses thereof | |
| IL271696A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| GB2595980B (en) | Anti-TCR antibody molecules and uses thereof | |
| SG10201912366YA (en) | Anti-cd3 antibody and molecules comprising the antibody | |
| GB2597851B (en) | Antibody molecules that bind to NKP30 and uses thereof | |
| GB2598218B (en) | Anti-TCR antibody molecules and uses thereof | |
| IL275577A (en) | Antibodies and variants thereof against pd-l1 | |
| GB2607452B (en) | Anti-TCR antibody molecules and uses thereof | |
| GB201811403D0 (en) | Antibody molecules | |
| SG11202103221QA (en) | Anti pd-l1 antibody and use thereof | |
| IL292799A (en) | Anti-siglec-9 antibody molecules | |
| EP3322445A4 (en) | Antibody binding agents that bind acinetobacter and uses thereof | |
| GB201818283D0 (en) | Antibody molecules that bind PD-L1 and CD137 | |
| GB201811405D0 (en) | Antibody molecules that bind PD-L1 and CD137 | |
| GB201902594D0 (en) | Antibody molecules that bind pd-l1 and cd137 | |
| GB201818281D0 (en) | Antibody molecules that bind CD137 and OX40 | |
| GB201811407D0 (en) | Antibody molecules that bind CD137 and OX40 | |
| GB201902598D0 (en) | Antibody molecules that bind cd137 and ox40 | |
| GB201808589D0 (en) | Single domain antibodies that bind CD137 |